Replies to post #22143 on Regen BioPharma Inc (RGBP)

[LoveAndLight]

THIS IS HUGE! A wonderful development for REGEN! Thank you Dr. Lander! :-)
Great stuff 1~Eye! :-) The key words here are...
"Regen to have primary control and responsibility for any patenting and commercialization activities" :-)
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11065814

Blessings BE,
LoveAndLight :-)

[seldomhome]

Love it Jack! I'll bet we have a PR barrage over the next few months and all will be revealed! If the company has attracted the likes of Santosh Kesari and 16 well respected people in this field then they are on to something powerful! Look at all those respected doctors. This company is legit! They are going places!

[1~Eye~Jack!!]

~ RGBP = IT IS VERY CLEAR =.The~JV~thru~NIH~is~COMPLETELY~FUNDED!! ;-)

That is Why the 8k is such HUGE New$!! ;-)

RGBP,, NCATS, NIH, arRre NOT Allowed to disclose the Information of How much Money this is,, or how much cost arRre!! IMO,, its final Cost is not completely known,, but make NO Mistake,, this Collaboration is COMPLETELY FUNDED!! ...and for up to 3 Years!! ;-)

I Suggest EVERYONE Read the whole 8k! ;-)
...but here is the Funding Part! ;-)...it was so Important it was #1 on da Agreement, YO! ;-)
http://ih.advfn.com/p.php?pid=nmona&article=69735998

Background
1. NCATS and Collaborator want to collaborate on a research project; and
2. NCATS and Collaborator want to transfer between the laboratories of their investigators, during the term of this Agreement, confidential information and proprietary research materials required to conduct the research project.

Terms and Conditions

Article 1 DEFINITIONS
1.1 “Confidential Information” includes scientific, business, or financial information pertaining to the Research Project (defined below) that is designated as confidential by Provider (defined below). Confidential Information does not include information that: (i) is in the public domain other than as a result of a disclosure by Recipient (defined below) or any of Recipient’s representatives in violation of this Agreement; (ii) was in the possession of Recipient before disclosure by the Provider; (iii) is acquired by Recipient from a third party having no obligation of confidentiality to Provider; (iv) is hereafter independently developed by Recipient, without reference to Confidential Information received from Provider; or (v) Provider expressly authorizes Recipient to disclose.

...and there is Money to be Gained from the HUGE JV!!! ;-)

http://ih.advfn.com/p.php?pid=nmona&article=69735998

On December 15, 2015 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with the National Center for Advancing Translational Sciences (“NCATS”), which is a component of the National Institutes of Health (“NIH”), an agency of the U.S. Department of Health and Human Services

Inventions made in the course of the Research Project will be owned by the Party employing the inventor or inventors. Inventions that are invented jointly by employees of both Parties will be owned jointly.

The Parties, moreover, agree to enter into an inter-institutional agreement with respect to joint inventions, which shall authorize Regen to have primary control and responsibility for any patenting and commercialization activities and shall be negotiated in good faith based on the respective parties’ contributions to each Joint Invention.

This is Why I'm on a Boat Crui$e'n~NorRrth, YO!! ;-) ...& with my Flippy~Floppy$,,YO!! ;-)